drugset / Trial / NCT00045786
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
RandomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).
Timeline
- Start
- 2001-10
- Primary completion
- 2001-12
- Completion
- 2003-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDC-801 | Small molecule | 400 mg | Oral |
| Subject | CDC-801 | Small molecule | 800 mg | Oral |
| Subject | CDC-801 | Small molecule | 1200 mg | Oral |
| Subject | CDC-801 | Small molecule | 1500 mg | Oral |